Cytori Therapeutics Inc (CYTX) Downgraded to Neutral at B. Riley
Cytori Therapeutics Inc (NASDAQ:CYTX) was downgraded by stock analysts at B. Riley from a “buy” rating to a “neutral” rating in a research note issued to investors on Tuesday, Marketbeat Ratings reports.
A number of other analysts have also recently commented on the company. ValuEngine raised Cytori Therapeutics from a “strong sell” rating to a “sell” rating in a research report on Thursday, July 13th. Zacks Investment Research cut Cytori Therapeutics from a “buy” rating to a “hold” rating in a research report on Wednesday, July 12th. Finally, Maxim Group set a $10.00 price objective on Cytori Therapeutics and gave the company a “buy” rating in a research report on Monday, July 10th.
Shares of Cytori Therapeutics (CYTX) traded down 0.022% during mid-day trading on Tuesday, hitting $0.464. The stock had a trading volume of 443,297 shares. The firm’s market cap is $15.07 million. The stock’s 50-day moving average price is $0.99 and its 200-day moving average price is $1.29. Cytori Therapeutics has a 52-week low of $0.41 and a 52-week high of $2.29.
Cytori Therapeutics (NASDAQ:CYTX) last issued its quarterly earnings results on Thursday, May 11th. The biotechnology company reported ($0.26) EPS for the quarter, topping analysts’ consensus estimates of ($0.31) by $0.05. Cytori Therapeutics had a negative return on equity of 177.92% and a negative net margin of 491.71%. The firm had revenue of $0.60 million for the quarter, compared to analysts’ expectations of $2.32 million. During the same period in the previous year, the firm posted ($0.03) EPS. The business’s revenue for the quarter was down 53.8% compared to the same quarter last year. On average, analysts anticipate that Cytori Therapeutics will post ($0.83) earnings per share for the current fiscal year.
A hedge fund recently raised its stake in Cytori Therapeutics stock. Perkins Capital Management Inc. raised its stake in shares of Cytori Therapeutics Inc (NASDAQ:CYTX) by 99.0% during the second quarter, according to its most recent filing with the SEC. The fund owned 874,896 shares of the biotechnology company’s stock after buying an additional 435,217 shares during the period. Cytori Therapeutics makes up 1.1% of Perkins Capital Management Inc.’s portfolio, making the stock its 28th largest position. Perkins Capital Management Inc. owned about 2.69% of Cytori Therapeutics worth $962,000 as of its most recent filing with the SEC. 8.65% of the stock is owned by institutional investors and hedge funds.
About Cytori Therapeutics
Cytori Therapeutics, Inc (Cytori) is a biotechnology company engaged in the development of treatments and devices for a range of disorders using cells as a key part of the therapy. The Company develops cellular therapeutics formulated and optimized for specific diseases and medical conditions and related products.
Receive News & Ratings for Cytori Therapeutics Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cytori Therapeutics Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.